Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma
Peroxiredoxins (Prxs) 1–6 were assessed in 138 renal cell carcinomas (RCC) using immunohistochemistry and selected samples by Western blotting analysis. Oxidative/nitrosative damage was evaluated using nitrotyrosine immunoreactivity. The expressions of Prxs were correlated with tumor grade and survival and nitrotyrosine reactivity. Non-malignant kidney tubular cells showed positivity with variable intensity for all six Prxs. In RCCs, most cases were positive for Prxs 1 and 2, while only 15–20% of tumors showed expression for Prxs 3 and 4. Prx 2 was associated with tumors of a lower grade (p=0.009) and with a lower frequency of distant metastases (p=0.046). Patients with tumors expressing Prx2 had better prognosis (p=0.027). Instead, nitrotyrosine was significantly associated with high grade tumors (p=0.001). Compared with the non-malignant kidney tubular cells, low Prx expression in the tumor cells can make them more susceptible to oxidative damage. Prx 2 was more abundantly expressed in low grade tumors, suggesting that this protein could play a role in preventing the development of oxidative damage, which in turn can lead to the activation of pathways leading to aggressive tumors.
Document Type: Research Article
Affiliations: 1: Department of Urology, Tampere University Hospital, Tampere, 2: Department of Pathology, University of Oulu, 3: HUSLAB, Division of Pathology, Helsinki University Central Hospital, Helsinki, 4: Department of Oncology, Tampere University Hospital and Medical School, University of Tampere, Finland 5: The Center for Cell Signalling Research and Division of Molecular Life Sciences, Ewha Womans University, Seoul, Korea 6: Department of Urology, Tampere University Hospital, and Medical School, University of Tampere, Tampere, 7: Department of Biochemistry, University of Oulu, Oulu, 8: Department of Pathology, Tampere University Hospital, Tampere, 9: Department of Medicine, Division of Pulmonary Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Publication date: 2006-05-01